title: Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.
abstract: We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 levels in bronchoalveolar lavage fluid and ovalbumin-specific serum IgE antibody levels were also significantly reduced. Treatment with pirfenidone significantly reduced transforming growth factor-beta1 and platelet-derived growth factor levels in bronchoalveolar lavage fluid. Pirfenidone reduced the expression of transforming growth factor-beta1, the development of goblet cell hyperplasia and subepithelial collagenization, and the increases in contractile elements in the lung. These data indicate that pirfenidone may play an important role in the treatment of asthma and has the potential reduce or prevent airway remodeling.
authors: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.
authors: Atsushi
authors: A
authors: Hirano
authors: Arihiko
authors: A
authors: Kanehiro
authors: Katsuichiro
authors: K
authors: Ono
authors: Wataru
authors: W
authors: Ito
authors: Akio
authors: A
authors: Yoshida
authors: Chiharu
authors: C
authors: Okada
authors: Hiromi
authors: H
authors: Nakashima
authors: Yasushi
authors: Y
authors: Tanimoto
authors: Mikio
authors: M
authors: Kataoka
authors: Erwin W
authors: EW
authors: Gelfand
authors: Mitsune
authors: M
authors: Tanimoto